Biotechnology
NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2025-02-24 07:56
2665
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD)cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg). - ASC30 oral once-daily tablet also demonstrated a 4.3% mean body weight reduction fr...
2025-02-19 20:00
3043
Hong Kong to Host Landmark International Symposium on Genomic Medicine
HKGI Partners with Global Leaders to Chart a Course for Healthcare Transformation HONG KONG, Feb. 19, 2025 /PRNewswire/ -- Genomic medicine has been gaining global prominence for its vast potential to revolutionise healthcare services. In the case of rare conditions, genomic medicine has been pa...
2025-02-19 11:43
2713
Berlin Heals Holding AG Successfully Raises Over 7Million CHF Round for Initiating First Studies of New Less Invasive Approaches
ZUG, Switzerland, Feb. 18, 2025 /PRNewswire/ -- Berlin Heals Holding AG, a late stage MedTech start up, has developed a breakthrough method and a product for the therapy of heart failure. The product - an electronic device called C-MIC - has already successfully been tested in patients in a pilot...
2025-02-18 23:20
2538
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy
REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as...
2025-02-17 19:25
2068
Vitafoods India 2025: Angel Yeast Brings Innovative Yeast Protein to Dining Table
MUMBAI, India, Feb. 17, 2025 /PRNewswire/ -- Angel Yeast
2025-02-17 12:01
2850
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-02-17 08:00
3038
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
* XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adultpatients with relapsed/refractory multiple myeloma (R/R MM). * After the mainland of China, South Korea, Australia and Singapore, Taiwan market is the fifth APAC market in which XPOVIO® has been approved for pu...
2025-02-13 17:30
3264
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
SUZHOU, China, Feb. 13, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the e...
2025-02-13 13:18
2476
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held inSan Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd （"Kelun-Biotech" will present efficacy and safety ...
2025-02-13 11:25
2025
Southern Star Research Applauded by Frost & Sullivan for Delivering Comprehensive Clinical Trial Solutions and Its Competitive Strategies
Southern Star sets itself apart in the CRO market through a unique combination of trust, operational advantages, deep industry expertise, and a strong commitment to local resources. SAN ANTONIO, Feb. 13, 2025 /PRNewswire/ -- Frost & Sullivan recently analyzed the biotechnology contract research ...
2025-02-13 10:30
2124
Sequential and AMILI Secure Prestigious $1.8M UK-Singapore Collaborative R&D Project to Advance Gut-Skin Microbiome Science
LONDON, Feb. 13, 2025 /PRNewswire/ -- Sequential Skin Ltd, a world leader in skin microbiome testing, and AMILI, a leading expert in gut microbiome science, are proud to announce that they have been awarded the prestigious UK-Singapore Collaborative R&D Grant. The$1.8 million project, supported b...
2025-02-13 06:00
2648
Lion TCR's Liocyx-M004 Receives FDA Clearance to Launch Global Multicenter Phase 2 Clinical Trial in HBV-Related Hepatocellular Carcinoma
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial. This ...
2025-02-12 09:00
4169
Sustainable Leather Technology Advances With Collaboration Between Meatable and Pelagen
LEIDEN, Netherlands, Feb. 11, 2025 /PRNewswire/ -- Meatable, a leader in cultivated meat technology, has started a collaboration effort withPelagen, a pioneering company focused on developing animal-free leather. This collaboration enables Pelagen to explore the use of the award-winning opti-ox™ ...
2025-02-11 20:04
2522
Infinitus Secures Approval for National-Level Joint Laboratory Project, Ushering in a New Chapter of China-Europe Scientific Research Collaboration
GUANGZHOU, China, Feb. 10, 2025 /PRNewswire/ – In a significant announcement at the recent Infinitus Global Annual Meeting, Infinitus (China) Company Ltd. secured approval for its Sino-British Joint Laboratory on Health and Aging project. This initiative is part of the intergovernmental internati...
2025-02-11 15:27
2746
Bio X Cell Expands Global Reach with New Distribution Center in Beijing, China
LEBANON, N.H., Feb. 11, 2025 /PRNewswire/ -- Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global distribution network with the opening of a new distribution center in Beijing, China, in March 2025. This expansion marks the lates...
2025-02-11 15:00
2061
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along wit...
2025-02-06 19:40
3585
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (...
2025-02-06 14:05
3559
Medidata Advances New Frontiers for Life Sciences Through Patient-Centric Experiences, AI-Powered Innovations, and New Patient Engaging Alliances
In the era of the generative economy, Medidata is transforming how industries
are empowering patients with new cure and care experiences and lifelong
engagement
SINGAPORE, Feb. 6, 2025 /PRNewswire/ -- Medidata
2025-02-06 13:00
4070
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC * Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC * Serplulimab has now been approved in China, Europe, and sev...
2025-02-05 22:05
3613
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 290 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 285 media titles]
2025-12-10 16:00
